Table 1.
Basic characteristics of included studies
| Study | Year | Study design | No. of cases | Age (mean range) | Disease stages | Histologic subtype | Magnet strenth (T) | Duration of the patients (years, month) | Blind | Timing of evaluation |
|---|---|---|---|---|---|---|---|---|---|---|
| Agarwal | 2017 | NR | 38 | 44.2(19–65) | LABC, stage II/III | IDC/DCIS | 1.5 T | NR | Pre-NAC and after 1.3 cycles | |
| Atuegwu | 2013 | NR | 28 | 44.9 (28–67) | Stage II/III | NR | 3.0 T | NR | Pre-NAC and after 1 cycle, and post-NAC | |
| Belli | 2011 | Pro | 51 | 48.4 (26–66) | NR | IDC/ILC | 1.5 T | 2007.01–2009.01 | Blind | Pre-NAC and post-NAC within 4 weeks |
| Bufi | 2014 | Retro | 225 | 47 (26–67) | Stage II/III | IDC/ILC | 1.5 T | 2007–2012 | Blind | Pre-NAC and post-NAC within 4 weeks |
| Bufi | 2015 | Retro | 225 | 47 (26–67) | LABC, stage II/III/IV | IDC/ILC | 1.5 T | 2007–2012 | Blind | Pre-NAC and post-NAC within 4 weeks |
| Che | 2016 | NR | 36 | 50.9 (27–75) | LABC | IDC/ILC | 3.0 T | 2014.03–2015.05 | Blind | Pre-NAC and after 2 cycles |
| Fangberget | 2010 | Pro | 31 | 50.7 (37–72) | Stage II/III/IV | IDC/ILC | 1.5 T | 2007.04–2008.10 | Blind | Pre-NAC and after 4 cycles, and post-NAC |
| Fujimoto | 2013 | NR | 56 | 50.9(27–70) | Stage II/III | IDC | 1.5 T | 2006.02–2009.12 | Blind | Pre-NAC and post-NAC within 3 weeks |
| Li | 2011 | Pro | 32 | 46 (25–63) | LABC | NR | 1.5 T | 2007.07–2010.07 | Pre-NAC and after 1 cycle | |
| Li | 2015 | Pro | 42 | 46.8 (28–67) | Stage II/III | NR | 3.0 T | NR | Pre-NAC and after 1 cycle, post-NAC | |
| Luo | 2014 | Retro | 71 | 46.1 (29–72) | NR | IDC | 3.0 T | 2010.03–2012.12 | Blind | Pre-NAC, after 2 cycles and post-NAC |
| Mani | 2013 | NR | 28 | 45 (28–67) | Stage II/III | NR | NR | NR | Pre-NAC, after 1 cycle and post-NAC | |
| Study | Year | Study design | No. of cases | Age (mean range) | Disease stages | Histologic subtype | Magnet strenth(T) | Duration of the patients (year, months) | Blind | Timing of evaluation |
| Park | 2010 | Retro | 53 | 43.7 (24–65) | Stage II/III | IDC/ILC | 1.5 T | 2007.03–2008.05 | Blind | Pre-NAC and after 3 cycles |
| Park | 2011 | Retro | 34 | 44 (27–60) | LABC | IDC/ILC | 1.5 T | 2007.04–2008.05 | Blind | Pre-NAC and after 3–6 cycles |
| Richard | 2013 | Retro | 118 | 53.2 (23–83) | LABC, stage II/III/IV | IDC/ILC | 1.5 T | 2008.07–2011.05 | Blind | Pre-NAC and post-NAC less than 2 weeks |
| Sharma | 2009 | Retro | 56 | 48.5 (25–75) | LABC | IDC | 1.5 T | 2003.12–2006.12 | Pre-NAC and after 1, 2, 3 cycles | |
| Shin | 2012 | Retro | 90 | 46 (24–68) | Stage I/II/III | IDC/ILC | 1.5 T | 2009.01–2011.05 | Pre-NAC and post-NAC | |
| Weis | 2015 | Retro | 33 | 46 (28–67) | Stage II/III | NR | 3.0 T | NR | Pre-NAC, after 1 cycle and post-NAC | |
| Woodhams | 2010 | NR | 69 | NR | NR | IDC/ILC | 1.5 T | 2005.01–2008.10 | Blind | Pre-NAC, after 4 cycles the post-NAC |
| Xu | 2017 | NR | 174 | 45.7 (28–64) | LABC, stage II/III | IDC/ILC | 3.0 T | 2011.09–2014.12 | Blind | Pre-NAC, after 1 cycle and post-NAC |
LABC locally advanced breast cancer; IDL invasive ductal carcinoma; ILC invasive lobular carcinoma; Pro prospective; Retro retrospective; NR not reported